Quanterix Corporation (QTRX)
After hours:
| Previous close | 15.56 |
| Open | 15.64 |
| Bid | 15.53 x 100 |
| Ask | 15.62 x 100 |
| Day's range | 15.56 - 16.32 |
| 52-week range | 12.17 - 29.70 |
| Volume | |
| Avg. volume | 369,264 |
| Market cap | 595.89M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.80 |
Business WireQuanterix To Report First Quarter 2024 Financial Results
BILLERICA, Mass., April 29, 2024--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results.
Simply Wall St.Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
Quanterix Corporation ( NASDAQ:QTRX ) shareholders might be concerned after seeing the share price drop 13% in the last...
Business WireQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
BILLERICA, Mass., March 21, 2024--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic testing services. Quanterix has secured over thirty U.S. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both in
